Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Stopped Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons

Conditions

• Parkinson's Disease

Interventions

• DRUG: Pimavanserin
• OTHER: Placebo
• DRUG: Quetiapine

Sponsor

ACADIA Pharmaceuticals Inc.